Aizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics

PartnershipPositive

AI Analysis

Summary

Aizen Therapeutics entered into a multi-program collaboration with San Diego Biopharma focused on advancing oral biologics, with revenue potential of $100 million per target.

Financial Highlights

Revenue

$100 million per target

Importance:7/10

Sentiment:

0.60

partnershipcollaborationoral biologicsmulti-program dealAI-native

Related Companies

$CBDY

Read the original article

Published by PR Newswire Pharma on August 15, 2026 11:20 AM

Read Original